Cardiac Fibrosis - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cardiac Fibrosis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cardiac Fibrosis - Pipeline Review, H1 2015', provides an overview of the Cardiac Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cardiac Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cardiac Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cardiac Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cardiac Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cardiac Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cardiac Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cardiac Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cardiac Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cardiac Fibrosis Overview 7
Therapeutics Development 8
Pipeline Products for Cardiac Fibrosis - Overview 8
Pipeline Products for Cardiac Fibrosis - Comparative Analysis 9
Cardiac Fibrosis - Therapeutics under Development by Companies 10
Cardiac Fibrosis - Therapeutics under Investigation by Universities/Institutes 11
Cardiac Fibrosis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Cardiac Fibrosis - Products under Development by Companies 14
Cardiac Fibrosis - Products under Investigation by Universities/Institutes 15
Cardiac Fibrosis - Companies Involved in Therapeutics Development 16
AstraZeneca PLC 16
BioLineRx, Ltd. 17
Daiichi Sankyo Company, Limited 18
Digna Biotech, S.L. 19
Galectin Therapeutics, Inc. 20
miRagen Therapeutics, Inc. 21
ProMetic Life Sciences Inc. 22
Cardiac Fibrosis - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
AZ-876 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CARD-024 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CGEN-856 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
disitertide - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GM-CT-01 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GR-MD-02 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MGN-4220 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
P-17 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PBI-4050 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PN1-Ab - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SP-20102 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
TM-5441 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Cardiac Fibrosis - Recent Pipeline Updates 52
Cardiac Fibrosis - Dormant Projects 64
Cardiac Fibrosis - Product Development Milestones 65
Featured News & Press Releases 65
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables

Number of Products under Development for Cardiac Fibrosis, H1 2015 8
Number of Products under Development for Cardiac Fibrosis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Cardiac Fibrosis - Pipeline by AstraZeneca PLC, H1 2015 16
Cardiac Fibrosis - Pipeline by BioLineRx, Ltd., H1 2015 17
Cardiac Fibrosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 18
Cardiac Fibrosis - Pipeline by Digna Biotech, S.L., H1 2015 19
Cardiac Fibrosis - Pipeline by Galectin Therapeutics, Inc., H1 2015 20
Cardiac Fibrosis - Pipeline by miRagen Therapeutics, Inc., H1 2015 21
Cardiac Fibrosis - Pipeline by ProMetic Life Sciences Inc., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 29
Number of Products by Stage and Molecule Type, H1 2015 31
Cardiac Fibrosis Therapeutics - Recent Pipeline Updates, H1 2015 52
Cardiac Fibrosis - Dormant Projects, H1 2015 64